Accurate assessment of gender identity and biological sex in dermatology research is crucial since their conflation or poor demarcation undermines patient respect and study accuracy. Clearer guidance is needed for health care researchers, particularly in light of the notable disparities in skin disease rates, skincare practices, literature representation, and the persistent underrepresentation of transgender and nonbinary patients.JMIR Dermatol 2023;6:e47118
Although gender identity is a social determinant of health, its assessment in health care research is inadequate. We highlight the intricacy of gender and biological sex in dermatology research, revealing the need for more robust protocols for their assessment. We begin by evaluating the current protocols used to make such assessments, demonstrating lack of consensus. Next, we evaluate the relationships between biological sex and gender identity and how these impact skin health. We then examine the inadequate representation of gender minorities—including those who identify as transgender or gender nonbinary—in academic literature and how this disparity compromises the applicability of evidence-based medicine to all. Finally, we consider the importance of physician communication about gender identity.
The articles analyzed in this study emphasize the importance of transparency when delineating differences between biological sex and gender identity. In addition, researchers should be coached on techniques to extinguish investigators’ biases. The models and tools for discerning gender identity and biological sex are shown in.
Note that the results obtained from the above methods were analyzed in conjunction with other questionnaires to assess correlations between the factors affecting overall population health [, , ]. Gender identity assessment tools must be regularly updated to accurately reflect the specific generational, cultural, and institutional contexts of the time.
Tools for discerning gender identity and biological sex.
- Stanford Gender-Related Variables for Health Research (GVHR) [ ]
- Bem Sex-Role Inventory (BSRI) [ , ]
- BSRI: short form [ , ]
- GENESIS-PRAXY (Gender and Sex Determinants of Cardiovascular Disease: From Bench to Beyond-Premature Acute Coronary Syndrome) [ ]
Guidelines and recommendations
- Sex and Gender Equity in Research (SAGER) guidelines [ ]
- Sex-gender variable: methodological recommendations for increasing scientific value of clinical studies [ ]
Gender Differences in Dermatologic Health
Cisgender (gender identity corresponds to sex assigned at birth) males and females exhibit different rates of various skin diseases . Increased awareness of gender differences is central to constructing mechanisms for prevention, diagnosis, and therapy [ ]. Those assigned male at birth tend to have higher sebum content, thicker skin, and deeper facial wrinkles than those assigned female [ ]. However, research regarding gender and dermatologic care is limited. Most articles discuss gender in terms of cisgendered participants. This research is likely based on the conflation of biological sex and gender identity in electronic health records [ ]. Systemic change within electronic health records is a critical step for gathering gender-precise data.
Gender-affirming therapies may induce drastic skin changes. Hormone therapies increase the risk of acne vulgaris, androgenetic alopecia, excessive sebum production, melasma, and hirsutism . Dermatologists must be conscious of gender-affirming treatments in order to help minimize associated risks.
Gender Minorities in Literature Representation
Researchers believe numerous factors contribute to skin differences between gender identities . Transmale and transfemale populations (gender identity does not correspond with sex assigned at birth) face underdiagnosed conditions resulting from underresearched gender-affirming therapies [ ]. This representation disparity is a growing area of investigation for its contribution to gender inequality.
Gender minority populations also face health care barriers from noninclusive treatment eligibility models. For instance, despite the increased prevalence of acne vulgaris in transgender populations, iPledge medication guidelines for isotretinoin use sex assigned at birth and require contraception to remain eligible .
Although increasing female participation in clinical trials is widely supported, data on gender minority participation is nonexistent. Additionally, the risks of some conditions fluctuate depending on the stage of gender-affirming therapies. Although existing data sets may not use inclusive models of gender identity assessment, there is value in their implementation given the prospect of large-scale observational studies and meta-analyses in which these variables could be better assessed. As gender minority populations grow, these inclusive models will help physicians support all patients while ensuring that salient trends and health impacts are captured by research analyses.
About 28% of transgender individuals delay seeking preventative care because of mistreatment by health care workers; thus, inclusive language is important to build trust in these communities . Medical professionals should receive training in gender-inclusive terminology to foster a welcoming environment where patients feel comfortable sharing information relevant to their health [ ]. Physicians should avoid assumptions and ask patients about their preferred terminology [ ]. displays a “Genderbread Person” and provides guidance on the terminology used in this paper.
Misgendering patients can have profound effects on patients’ health and safety and can damage the patient-provider relationship . As ideas about gender identity evolve, mistakes will inevitably happen; when mistakes occur, sincere and brief apologies should be made, with an assurance that they will not recur [ ].
Robust methodologies exist to eliminate subjectivity and maximize data accuracy and utility. Current approaches to distinguishing gender identity and biological sex are inadequate and threaten the applicability of research findings to many patients. Conflating sex and gender neglects the unique dermatologic health impacts of these attributes and contributes to the underrepresentation of gender minority populations in medical literature. While more research is needed to address these issues, communication training for physicians and other health care providers could be improved. The language used must respect patients’ identities while maintaining objectivity in clinical research.
Conflicts of Interest
RD is an editorial board member of Cochrane Skin and the Journal of the American Academy of Dermatology, a dermatology section editor for UpToDate, and editor-in-chief of JMIR Dermatology. He is a coordinating editor representative on Cochrane Council and Cochrane Council cochair. He receives editorial stipends (JMIR Dermatology), royalties (UpToDate), and expense reimbursement from Cochrane. TES is an editorial board member-at-large for JMIR Dermatology. She receives fellowship funding from the National Institutes of Health (grant 2T32AR00741136A1; principal investigator: Dennis Roop). The other authors declare no conflicts of interest.
- Nielsen MW, Stefanick ML, Peragine D, Neilands TB, Ioannidis JPA, Pilote L, et al. Gender-related variables for health research. Biol Sex Differ 2021 Feb 22;12(1):23 [https://bsd.biomedcentral.com/articles/10.1186/s13293-021-00366-3] [CrossRef] [Medline]
- Conger K. Of mice, men, and women: making research more inclusive. Stanford Medicine Magazine. 2017 May 22. URL: https://stanmed.stanford.edu/how-sex-and-gender-which-are-not-the-same-thing-influence-our-health/ [accessed 2022-08-01]
- Clayton JA, Tannenbaum C. Reporting sex, gender, or both in clinical research? JAMA 2016 Nov 08;316(18):1863-1864 [CrossRef] [Medline]
- Franconi F, Campesi I, Colombo D, Antonini P. Sex-gender variable: methodological recommendations for increasing scientific value of clinical studies. Cells 2019 May 17;8(5):476 [https://www.mdpi.com/resolver?pii=cells8050476] [CrossRef] [Medline]
- Chen W, Mempel M, Traidl-Hofmann C, Al Khusaei S, Ring J. Gender aspects in skin diseases. J Eur Acad Dermatol Venereol 2010 Dec;24(12):1378-1385 [CrossRef] [Medline]
- Rahrovan S, Fanian F, Mehryan P, Humbert P, Firooz A. Male versus female skin: what dermatologists and cosmeticians should know. Int J Womens Dermatol 2018 Sep;4(3):122-130 [https://linkinghub.elsevier.com/retrieve/pii/S2352-6475(18)30013-3] [CrossRef] [Medline]
- Davison K, Queen R, Lau F, Antonio M. Culturally competent gender, sex, and sexual orientation information practices and electronic health records: rapid review. JMIR Med Inform 2021 Feb 11;9(2):e25467 [https://medinform.jmir.org/2021/2/e25467/] [CrossRef] [Medline]
- Yeung H, Kahn B, Ly BC, Tangpricha V. Dermatologic conditions in transgender populations. Endocrinol Metab Clin North Am 2019 Jun;48(2):429-440 [https://europepmc.org/abstract/MED/31027550] [CrossRef] [Medline]
- Seelman KL, Colón-Diaz MJP, LeCroix RH, Xavier-Brier M, Kattari L. Transgender noninclusive healthcare and delaying care because of fear: connections to general health and mental health among transgender adults. Transgend Health 2017 Dec;2(1):17-28 [https://europepmc.org/abstract/MED/28861545] [CrossRef] [Medline]
- Killermann S. The Genderbread Person, version 4. Genderbread.org. 2017. URL: https://www.genderbread.org/ [accessed 2023-06-27]
- Berg S. 6 things patients wish physicians knew about gender identity. American Medical Association. 2021 Jun 25. URL: https://www.ama-assn.org/delivering-care/population-care/6-things-patients-wish-physicians-knew-about-gender-identity [accessed 2022-06-06]
Edited by J Lipoff; submitted 08.03.23; peer-reviewed by K Davison, C Burnette; comments to author 04.04.23; revised version received 28.05.23; accepted 20.06.23; published 18.07.23Copyright
©Noah N Nigro, Neal Chandnani, Athena Doshi, Alexa Fritsch, Nathaniel A Marroquin, Morgan Zueger, Torunn E Sivesind, Robert Dellavalle, Cory Dunnick. Originally published in JMIR Dermatology (http://derma.jmir.org), 18.07.2023.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Dermatology, is properly cited. The complete bibliographic information, a link to the original publication on http://derma.jmir.org, as well as this copyright and license information must be included.